Table 2. Peto odds ratio of adverse events related to dual anti-HER2 treatment.
| Adverse outcome (grade ≥3) | Trials (n) | No. of patients (n) | I2 | Peto Odds Ratio (95%CI) | p | |
|---|---|---|---|---|---|---|
| Dual anti-HER2 agents, Events/total | Anti-HER2 monotherapy,Events/total | |||||
| Diarrhea | 9 | 557/3649 | 431/5992 | 49% | 2.52(95%CI: 2.20-2.89) | <0.001 |
| Rash | 9 | 196/3649 | 238/5992 | 61% | 1.06 (95%CI:0.67-1.68) | 0.81 |
| Liver toxicities | 6 | 100/2723 | 168/5115 | 43% | 1.16 (95%CI:0.89-1.50) | 0.28 |
| CHF | 9 | 42/3649 | 47/5992 | 46% | 1.46(95%CI: 0.94-2.26) | 0.09 |
| LVEF decline | 9 | 209/3649 | 296/5992 | 49% | 1.09(95%CI:0.90-1.31) | 0.40 |
| AEs lead to permanent treatment discontinuation | 9 | 681/3649 | 684/5992 | 74% | 1.52(95%CI: 1.09-2.12) | 0.014 |
| FAEs | 9 | 28/3649 | 39/5992 | 0% | 0.97(95%CI: 0.59-1.59) | 0.91 |
I2≥50% suggests high heterogeneity across studies.
Abbreviation: CHF, congestive heart failure, LVEF, left ventricular ejection fraction; FAEs, Fatal adverse events.